Feb. 21, 2012
/PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries and marketer of
), its recently launched line of dietary supplements, announced today the Board has appointed
Debra A. Heim
as the company's Chief Operating Officer and President of its Consumer Products Division.
, age 43, has over 20 years of experience with consumer brands companies. Prior to joining ChromaDex, Ms. Heim spent 16 years with
The Himmel Group
) where she served as its President and Chief Operating Officer since 2010. Previously, she served as the company's Chief Financial Officer for 12 years. During her tenure with The Himmel Group, Ms. Heim was part of the executive management team overseeing sales and marketing of the GOLD BOND MEDICATED POWDER and OVALTINE® businesses. Additionally, Debra built and managed the organization responsible for the manufacturing, sales order processing, distribution, accounting and finance, information technology systems, human resources and consumer services of the company.
Commenting on the announcement, ChromaDex's CEO
stated, "Having personally worked with Debra for more than 15 years, I am thrilled to have her join the executive management team at ChromaDex. Her experience and skill sets with branded consumer products are an ideal fit, as we are just beginning the national retail launch of our
line of dietary supplements."
About ChromaDex ®:
ChromaDex, Inc. is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an expanding pipeline of new ingredients, including its
) pterostilbene for which it has worldwide, exclusive patent pending rights. The company recently launched its
line of dietary supplements. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure
for the skincare and pharmaceutical markets, among others. pTeroPure
is currently being studied in a human clinical trial at the
University of Mississippi
For more information about pTeroPure
or call 949-600-9694.
Any statements that are not historical facts contained in this release are "forward-looking statements" as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the companies' filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the companies do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.